[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eus":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100627418","eus-guided-ctcs--multi-omics-predicting-pancreatic-cancer-recurrence-and-metastases-100627418",false,"NCT07448376","EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases","Exploratory Study on EUS-guided Portal Vein CTCs and Their Subtypes Combined With Multi-omics Detection for Early Warning of Pancreatic Cancer Recurrence and Metastasis","Inclusion Criteria:\n\n1. Patients with solid masses (diameter \\> 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.\n2. Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT\u002FMRI).\n3. Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.\n4. Signed informed consent form.\n5. Patients must be able to comply with the trial requirements.\n\nExclusion Criteria:\n\n1. Patients with other active malignant tumors\n2. Patients with coagulation dysfunction (PLT 50,000\u002Fmm3, INR \\> 1.5; roughly estimated, INR \\> 1.5 is approximately equivalent to PT \\> 18 seconds)\n3. Pregnant women\n4. Patients with hemorrhagic diseases\n5. Patients with a history of taking anticoagulant drugs such as aspirin and warfarin in the past week\n6. Patients with absolute contraindications to EUS examination, a history of acute pancreatitis within the past 2 weeks, a history of gastric surgery, pregnancy, severe diseases, or a history of allergy to anesthetics\n7. Patients whose EUS examination was terminated early due to esophageal stenosis, obstruction, large space-occupying lesions, rapid changes in the patient's heart rate or respiratory rate, patient intolerance, or a large amount of food residue, etc.\n8. Patients with known hepatitis C virus infection\n9. Patients with known human immunodeficiency virus (HIV) infection\n10. Patients with imaging examinations, EUS results, etc., suggesting pancreatic cystic space-occupying lesions\n11. Patients who have received radiotherapy or chemotherapy\n12. Patients with incomplete pathological information, unable to make a clear diagnosis, or unable to sign the informed consent form","ALL","18 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","2 Years","OBSERVATIONAL","The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).",[26,27,28,29,30,31,32],"CTCs","Pancreatic Cancer","Liver Metastases","Relapse","Borderline Resectable Pancreatic Cancer","Resectable Pancreatic Cancers","EUS",[32,34,27,35,36,37,38],"CTC","metastases","relapse","BRPC","RPC","NOT_YET_RECRUITING","2026-02-25",{"date":42,"type":43},"2026-03-04","ACTUAL",{"date":45,"type":21},"2026-03-01",{"date":47,"type":21},"2027-12-30",{"name":49,"class":50},"Huazhong University of Science and Technology","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":73,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":5},"100625617","hepatic-venous-pressure-gradient-versus-endoscopic-ultrasound-guided-portal-pressure-gradient---comparative-analysis-hepca-100625617","NCT07424963","Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)","Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis","HEPCA","Inclusion Criteria:\n\n* Age 18-75 years at the time of enrollment; signed informed consent\n* Clinical indication for HVPG measurement and\u002For transjugular liver biopsy for chronic advanced liver disease\n\nExclusion Criteria:\n\n* Severe co-morbidities (e.g., advanced chronic heart failure, chronic renal insufficiency stage 4 and above, long-term poorly compensated diabetes mellitus with severe complications)\n* Pregnancy\n* Estimated patient non-compliance and\u002For not signing of the informed consent\n* Documented iodine contrast dye allergy\n* Presence of portal vein thrombosis or cavernomatous transformation of portal vein or hepatic vein obstruction\n* Ascites Grade 3\n* Biliary obstruction\n* Anticoagulation or antiplatelet therapy, which cannot be discontinued\n* INR \\> 1.5 and\u002For platelet count \\\u003C 50,000\u002Fµl\n* Hepatocellular carcinoma in the left lobe of the liver\n* Surgically altered upper gastrointestinal tract anatomy\n* State after transjugular intrahepatic portosystemic shunt\n* State after liver transplantation","75 Years",{"count":62,"type":21},40,"INTERVENTIONAL",[65],"NA","The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement.\n\nThe primary question is whether EUS-PPG provides measurements really equivalent to HVPG in terms of gradient accuracy.\n\nParticipants undergoing HVPG will first undergo the procedure while conscious, performed by the first operator. Immediately thereafter, HVPG will be repeated following the induction of anesthesia by a second operator blinded to the initial readings. Subsequently, EUS-PPG will be performed by an endoscopist, who will also be blinded to all previous pressure measurements.",[68,69,32,70,71,72],"Cirrhosis","Portal Hypertension","Non-Cirrhotic Portal Hypertension","HVPG","Hepatic Venous Pressure Gradient",[71,74,75,76],"EUS-PPG","portal hypertension","liver cirrhosis","RECRUITING","2026-02-16",{"date":80,"type":43},"2026-02-20",{"date":82,"type":43},"2025-05-30",{"date":84,"type":21},"2028-12-31",{"name":86,"class":50},"Military University Hospital, Prague"]